PT  - JOURNAL ARTICLE
AU  - Tarjinder Singh
AU  - Benjamin M. Neale
AU  - Mark J. Daly
AU  - on behalf of the Schizophrenia Exome Meta-Analysis (SCHEMA) Consortium
TI  - Exome sequencing identifies rare coding variants in 10 genes which confer substantial risk for schizophrenia
AID  - 10.1101/2020.09.18.20192815
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.18.20192815
4099  - http://medrxiv.org/content/early/2020/09/18/2020.09.18.20192815.short
4100  - http://medrxiv.org/content/early/2020/09/18/2020.09.18.20192815.full
AB  - By meta-analyzing the whole-exomes of 24,248 cases and 97,322 controls, we implicate ultra-rare coding variants (URVs) in ten genes as conferring substantial risk for schizophrenia (odds ratios 3 - 50, P < 2.14 × 10-6), and 32 genes at a FDR < 5%. These genes have the greatest expression in central nervous system neurons and have diverse molecular functions that include the formation, structure, and function of the synapse. The associations of NMDA receptor subunit GRIN2A and AMPA receptor subunit GRIA3 provide support for the dysfunction of the glutamatergic system as a mechanistic hypothesis in the pathogenesis of schizophrenia. We find significant evidence for an overlap of rare variant risk between schizophrenia, autism spectrum disorders (ASD), and severe neurodevelopmental disorders (DD/ID), supporting a neurodevelopmental etiology for schizophrenia. We show that protein-truncating variants in GRIN2A, TRIO, and CACNA1G confer risk for schizophrenia whereas specific missense mutations in these genes confer risk for DD/ID. Nevertheless, few of the strongly associated schizophrenia genes appear to confer risk for DD/ID. We demonstrate that genes prioritized from common variant analyses of schizophrenia are enriched in rare variant risk, suggesting that common and rare genetic risk factors at least partially converge on the same underlying pathogenic biological processes. Even after excluding significantly associated genes, schizophrenia cases still carry a substantial excess of URVs, implying that more schizophrenia risk genes await discovery using this approach.Competing Interest StatementM.J.D. is a founder of Maze Therapeutics. B.M.N. is a member of the scientific advisory board at Deep Genomics and consultant for Camp4 Therapeutics, Takeda Pharmaceutical, and Biogen. A.P. is a member of Astra Zeneca's Genomics Advisory Board. M.C.O, M.J.O, and J.T.W. are supported by a collaborative research grant from Takeda Pharmaceuticals.Funding StatementWe would like to thank the patients and families who participated in our studies in the past two decades, without whom our research and findings would not be possible. Research reported in this publication was supported by the National Institute of Mental Health, and the National Human Genome Research Institute of the National Institutes of Health under award numbers: U01MH10564, U01MH105578, R01MH085548 and U54HG003067. We would also like to acknowledge the generous support from the Stanley Family Foundation, Kent and Elizabeth Dauten, and The Dalio Foundation who have enabled us to rapidly expand our data generation collections with the goal of moving towards better treatments for schizophrenia and other psychiatric disorders.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The cohort descriptions are provided in the Supplementary Methods.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe have provided data tables in the main text, Supplementary Methods, and in an exome results browser at https://schema.broadinstitute.org https://schema.broadinstitute.org/